


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5 HT receptor, comprising administering to a subject in need thereof an effective amount of a compound of formula I  
in which



- X denotes CH or N,  
R<sup>1</sup> denotes H, A, Hal, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms, CF<sub>3</sub>, NO<sub>2</sub>, CN, C(NH)NOH or OCF<sub>3</sub>,  
R<sup>2</sup> denotes (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms or CF<sub>3</sub>,  
R<sup>3</sup>, R<sup>4</sup> denote H, (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>COHet, (CH<sub>2</sub>)<sub>n</sub>CON(R<sup>5</sup>)<sub>2</sub>,  
(CH<sub>2</sub>)<sub>n</sub>COO(CH<sub>2</sub>)<sub>n</sub>Het, CHO, (CH<sub>2</sub>)<sub>n</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>,  
CH=N-OA, CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Het,  
(CH<sub>2</sub>)<sub>n</sub>CH=N-Het, (CH<sub>2</sub>)<sub>n</sub>OCOR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)C(R<sup>5</sup>)HCOOR<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>COHet, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)CH<sub>2</sub>COOR<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>,  
CH=CHCOOR<sup>5</sup>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>,  
CH=CHCH<sub>2</sub>OR<sup>5</sup>, CH=CHCH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar,  
(CH<sub>2</sub>)<sub>n</sub>N(COOR<sup>5</sup>)COOR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)COOR<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(CONH<sub>2</sub>)CONH<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>COOR<sup>5</sup>)COOR<sup>5</sup>,  
(CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>CONH<sub>2</sub>)COOR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(CH<sub>2</sub>CONH<sub>2</sub>)CONH<sub>2</sub>,  
(CH<sub>2</sub>)<sub>n</sub>CHR<sup>5</sup>COR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>CHR<sup>5</sup>COOR<sup>5</sup>, or (CH<sub>2</sub>)<sub>n</sub>CHR<sup>5</sup>CH<sub>2</sub>OR<sup>5</sup>,  
where in each case one of the radicals R<sup>3</sup> or R<sup>4</sup> has the meaning H,

$R^5$  denotes H or A  
A denotes straight-chain or branched alkyl having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,  
Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,  
Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal,  $OR^5$ ,  $OCOR^5$ ,  $COOR^5$ ,  $CON(R^5)_2$ , CN,  $NO_2$ ,  $NH_2$ ,  $NHCOR^5$ ,  $CF_3$  or  $SO_2CH_3$ ,  
n denotes 0, 1, 2, 3, 4 or 5, and  
Hal denotes F, Cl, Br or I,  
or a salt, solvate, enantiomer or racemate thereof.

2. (Currently Amended) A method compound according to claim 1, wherein the compound of formula I has a 5-HT receptor-antagonistic action.

3. (Currently Amended) A method compound according to claim 1, wherein the compound of formula I has a 5-HT<sub>2A</sub> receptor-antagonistic action.

4. (Currently Amended) A method according to claim 21-4, wherein the disease is psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

5. (Currently Amended) A method compound according to claim 1, in which  $R^1$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl.

6. (Currently Amended) A method compound according to claim 1, in which R<sup>3</sup> denotes (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>CO-Het, CHO, CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>-Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup>, CH=CHCH<sub>2</sub>Het or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar.

7. (Currently Amended) A method compound according to claim 1, in which R<sup>4</sup> denotes H.

8. (Currently Amended) A method compound according to claim 1, in which R<sup>2</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl.

9. (Currently Amended) A method compound according to claim 1, in which X has the meaning CH.


10. (Cancelled)

11. (Currently Amended) A method compound according to claim 1, wherein the compound of formula I is  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(4-methylpiperazin-1 -yl)amine;  
4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;  
4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;  
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;  
1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;

1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;  
2-{[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino}ethanol;  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-2-methoxyethyl)amine;  
2-{[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino}ethanol;  
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;  
1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine; or  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1-methylpyrrolidin-3-yl)amine;  
or a salt or solvate thereof.

12. (Currently Amended) A method according to claim 21 4, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

13. (Currently Amended) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5-HT receptor, comprising administering to a subject in need thereof an effective amount of a compound of formula I  
in which



X denotes CH or N,

R<sup>1</sup> denotes H, A, Hal, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms, CF<sub>3</sub>, NO<sub>2</sub>, CN, C(NH)NOH or OCF<sub>3</sub>,

$R^2$	denotes $(CH_2)_n$ Het, $(CH_2)_n$ Ar, cycloalkyl having 3 to 7 C atoms or $CF_3$ ,
$R^3, R^4$	denote H, $(CH_2)_nCO_2R^5$ , $(CH_2)_nCOH$ et, $(CH_2)_nCON(R^5)_2$ , $(CH_2)_nCOO(CH_2)_n$ Het, CHO, $(CH_2)_nOR^5$ , $(CH_2)_n$ Het, $(CH_2)_nN(R^5)_2$ , $CH=N-OA$ , $CH_2CH=N-OA$ , $(CH_2)_nNHOA$ , $(CH_2)_nN(R^5)Het$ , $(CH_2)_nCH=N-Het$ , $(CH_2)_nOCOR^5$ , $(CH_2)_nN(R^5)CH_2CH_2OR^5$ , $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ , $(CH_2)_nN(R^5)C(R^5)HCOOR^5$ , $(CH_2)_nN(R^5)CH_2COH$ et, $(CH_2)_nN(R^5)CH_2$ Het, $(CH_2)_nN(R^5)CH_2CH_2$ Het, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$ , $(CH_2)_nN(R^5)CH_2CH_2OR^5$ , $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ , $CH=CHCOOR^5$ , $CH=CHCH_2NR^5$ Het, $CH=CHCH_2N(R^5)_2$ , $CH=CHCH_2OR^5$ , $CH=CHCH_2$ Het, $(CH_2)_nN(R^5)Ar$ , $(CH_2)_nN(COOR^5)COOR^5$ , $(CH_2)_nN(CONH_2)COOR^5$ , $(CH_2)_nN(CONH_2)CONH_2$ , $(CH_2)_nN(CH_2COOR^5)COOR^5$ , $(CH_2)_nN(CH_2CONH_2)COOR^5$ , $(CH_2)_nN(CH_2CONH_2)CONH_2$ , $(CH_2)_nCHR^5COR^5$ , $(CH_2)_nCHR^5COOR^5$ , or $(CH_2)_nCHR^5CH_2OR^5$ , where in each case one of the radicals $R^3$ or $R^4$ has the meaning H,
$R^5$	denotes H or A
A	denotes straight-chain or branched alkyl having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,
Het	denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,
Ar	denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, $OR^5$ , $OCOR^5$ , $COOR^5$ , $CON(R^5)_2$ , CN, $NO_2$ , $NH_2$ , $NHCOR^5$ , $CF_3$ or $SO_2CH_3$ ,
n	denotes 0, 1, 2, 3, 4 or 5, and
Hal	denotes F, Cl, Br or I, or a salt thereof.

14. (Currently Amended) A method compound according to claim

13, wherein the compound of formula I is  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazin-1 -  
yl)amine;  
4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;  
4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;  
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;  
1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-  
methylpiperazine;  
1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-  
methylpiperazine;  
1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-  
methylpiperazine;  
N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;  
2-{{1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl}amino}ethanol;  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-2-methoxyethyl)amine;  
2-{{1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl}methylamino}ethanol;  
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-  
[1,4]diazepam;  
1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-  
methylpiperazine; or  
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -  
methylpyrrolidin-3-yl)amine;  
or a salt thereof.

15. (Currently Amended) A method according to claim 13, which is  
for the treatment of psychoses, a neurological disorder, amyotrophic lateral  
sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or  
obsessive-compulsive disorder (OCD), comprising administering to a subject in need  
thereof an effective amount of a compound according to claim 13.

16. (Currently Amended) A method according to claim 14, which is  
for the treatment of psychoses, a neurological disorder, amyotrophic lateral  
sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or

obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 14.

17. (Currently Amended) A method compound according to claim 1,  
in which

- R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,  
R<sup>3</sup> denotes (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>CO-Het, CHO, CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>-Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup>, CH=CHCH<sub>2</sub>Het or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar,  
R<sup>4</sup> denotes H,  
R<sup>2</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and  
X has the meaning CH.

18. (Currently Amended) A method compound according to claim 13,  
in which

- R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,  
R<sup>3</sup> denotes (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>CO-Het, CHO, CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>-Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>NR<sup>5</sup>Het, CH=CHCH<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=CHCH<sub>2</sub>OR<sup>5</sup>, CH=CHCH<sub>2</sub>Het or (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Ar,

- $R^4$  denotes H,
- $R^2$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and
- X has the meaning CH.

19. (Currently Amended) A method according to claim 17, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 17.

20. (Currently Amended) A method according to claim 18, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 18.

21. (New) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5 HT receptor, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.